A Phase 1 interventional study of ALXN1840 Enteric-coated Tablet and ALXN1840 Non-coated Capsule in Healthy, sponsored by Alexion Pharmaceuticals, Inc.. Completed at 1 site in United States. Open to participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-08-02.
Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This was single-center, open-label, randomized, 3-period, 3-treatment, 6-sequence crossover study evaluating the PK of single doses of WTX101 in healthy participants based on the measurement of plasma total Mo concentration.
Alexion Pharmaceuticals, Inc. is the lead sponsor of 255 studies on the registry; 23 are open to participants now.
Of its 101 completed or terminated interventional studies of FDA-regulated products, 75 (74%) have results posted.
First submitted after Alexion Pharmaceuticals, Inc. became part of AstraZeneca.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received each treatment on 1 occasion: Period 1 (Treatment A): ALXN1840 tablets following an overnight fast. Period 2 (Treatment B): ALXN1840 tablets after the start of a high-fat breakfast, preceded by an overnight fast. Period 3 (Treatment C): Omeprazole once daily in the morning of Days -5 to -1 following an overnight fast, omeprazole at Hour -1 on Day 1 following an overnight fast, and ALXN1840 non-coated capsules at Hour 0 on Day 1. There was a washout period of at least 14 days between each ALXN1840 dosing.
Drug: ALXN1840 Enteric-coated Tablet · Drug: ALXN1840 Non-coated Capsule · Drug: Omeprazole
Participants received each treatment on 1 occasion: Period 1 (Treatment A): ALXN1840 tablets following an overnight fast. Period 2 (Treatment C): Omeprazole once daily in the morning of Days -5 to -1 following an overnight fast, omeprazole at Hour -1 on Day 1 following an overnight fast, and ALXN1840 non-coated capsules at Hour 0 on Day 1. Period 3 (Treatment B): ALXN1840 tablets after the start of a high-fat breakfast, preceded by an overnight fast. There was a washout period of at least 14 days between each ALXN1840 dosing.
Drug: ALXN1840 Enteric-coated Tablet · Drug: ALXN1840 Non-coated Capsule · Drug: Omeprazole
Participants received each treatment on 1 occasion: Period 1 (Treatment B): ALXN1840 tablets after the start of a high-fat breakfast, preceded by an overnight fast. Period 2 (Treatment A): ALXN1840 tablets following an overnight fast. Period 3 (Treatment C): Omeprazole once daily in the morning of Days -5 to -1 following an overnight fast, omeprazole at Hour -1 on Day 1 following an overnight fast, and ALXN1840 non-coated capsules at Hour 0 on Day 1. There was a washout period of at least 14 days between each ALXN1840 dosing.
Drug: ALXN1840 Enteric-coated Tablet · Drug: ALXN1840 Non-coated Capsule · Drug: Omeprazole
Participants received each treatment on 1 occasion: Period 1 (Treatment B): ALXN1840 tablets after the start of a high-fat breakfast, preceded by an overnight fast. Period 2 (Treatment C): Omeprazole once daily in the morning of Days -5 to -1 following an overnight fast, omeprazole at Hour -1 on Day 1 following an overnight fast, and ALXN1840 non-coated capsules at Hour 0 on Day 1. Period 3 (Treatment A): ALXN1840 tablets following an overnight fast. There was a washout period of at least 14 days between each ALXN1840 dosing.
Drug: ALXN1840 Enteric-coated Tablet · Drug: ALXN1840 Non-coated Capsule · Drug: Omeprazole
Participants received each treatment on 1 occasion: Period 1 (Treatment C): Omeprazole once daily in the morning of Days -5 to -1 following an overnight fast, omeprazole at Hour -1 on Day 1 following an overnight fast, and ALXN1840 non-coated capsules at Hour 0 on Day 1. Period 2 (Treatment A): ALXN1840 tablets following an overnight fast. Period 3 (Treatment B): ALXN1840 tablets after the start of a high-fat breakfast, preceded by an overnight fast. There was a washout period of at least 14 days between each ALXN1840 dosing.
Drug: ALXN1840 Enteric-coated Tablet · Drug: ALXN1840 Non-coated Capsule · Drug: Omeprazole
Participants received each treatment on 1 occasion: Period 1 (Treatment C): Omeprazole once daily in the morning of Days -5 to -1 following an overnight fast, omeprazole at Hour -1 on Day 1 following an overnight fast, and ALXN1840 non-coated capsules at Hour 0 on Day 1. Period 2 (Treatment B): ALXN1840 tablets after the start of a high-fat breakfast, preceded by an overnight fast. Period 3 (Treatment A): ALXN1840 tablets following an overnight fast. There was a washout period of at least 14 days between each ALXN1840 dosing.
Drug: ALXN1840 Enteric-coated Tablet · Drug: ALXN1840 Non-coated Capsule · Drug: Omeprazole
ALXN1840 (60 milligrams) was administered orally as EC tablets at Hour 0 on Day 1.
Also known as: WTX101 (formerly), Bis-choline tetrathiomolybdate, Tiomolibdate choline
ALXN1840 (60 milligrams) was administered orally as non-coated capsules at Hour 0 on Day 1.
Also known as: WTX101 (formerly), Bis-choline tetrathiomolybdate, Tiomolibdate choline
Omeprazole (20 milligrams) was administered orally as a delayed-release capsule in the morning of Days -5 to -1 and at Hour -1 on Day 1.
Also known as: Prilosec
Area Under the Plasma Concentration Versus Time Curve, From Time 0 to the Last Measurable Concentration (AUC0-t) of Total Molybdenum (Mo)
AUC0-t was calculated by the linear trapezoidal method.
Time frame: Predose (0 hour) up to 192 hours postdose
Maximum Measured Plasma Concentration (Cmax) of Total Mo
Time frame: Predose (0 hour) up to 192 hours postdose
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
An adverse event (AE) was defined as any untoward medical occurrence in a participant administered with the study drug and which did not necessarily have a causal relationship with the study drug. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not related to study drug. A TEAE was defined as an AE that started or worsened at the time of or after study drug administration. An AE that occurred during the washout period between drugs was considered treatment emergent to the last drug given. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
Time frame: Day 1 through 14 days following final dose (up to Day 43)
| Milestone | Treatment Sequence 1: ABC | Treatment Sequence 2: ACB | Treatment Sequence 3: BAC | Treatment Sequence 4: BCA | Treatment Sequence 5: CAB | Treatment Sequence 6: CBA |
|---|---|---|---|---|---|---|
| Started | 3 | 3 | 3 | 3 | 3 | 3 |
| Received at least 1 dose of study drug | 3 | 3 | 3 | 3 | 3 | 3 |
| Completed | 3 | 3 | 3 | 3 | 3 | 3 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
AUC0-t was calculated by the linear trapezoidal method.
| hours*ng/mL | Treatment A: ALXN1840 (Fasted) | Treatment B: ALXN1840 (Fed) | Treatment C: Omeprazole + ALXN1840 (Fasted) |
|---|---|---|---|
| Area Under the Plasma Concentration Versus Time Curve, From Time 0 to the Last Measurable Concentration (AUC0-t) of Total Molybdenum (Mo) | 16026 ± 5635 | 5740 ± 4681 | 19809 ± 3509 |
| ng/mL | Treatment A: ALXN1840 (Fasted) | Treatment B: ALXN1840 (Fed) | Treatment C: Omeprazole + ALXN1840 (Fasted) |
|---|---|---|---|
| Maximum Measured Plasma Concentration (Cmax) of Total Mo | 376 ± 98.0 | 187 ± 118 | 442 ± 69.6 |
An adverse event (AE) was defined as any untoward medical occurrence in a participant administered with the study drug and which did not necessarily have a causal relationship with the study drug. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not related to study drug. A TEAE was defined as an AE that started or worsened at the time of or after study drug administration. An AE that occurred during the washout period between drugs was considered treatment emergent to the last drug given. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
| Participants | Treatment A: ALXN1840 (Fasted) | Treatment B: ALXN1840 (Fed) | Treatment C: Omeprazole + ALXN1840 (Fasted) |
|---|---|---|---|
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | 4 | 2 | 6 |
Collected over Day 1 through 14 days following final dose (up to Day 43). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment A: ALXN1840 (Fasted) | — | 0/18 (0%) | 4/18 (22.2%) |
| Treatment B: ALXN1840 (Fed) | — | 0/18 (0%) | 2/18 (11.1%) |
| Treatment C: Omeprazole + ALXN1840 (Fasted) | — | 0/18 (0%) | 6/18 (33.3%) |
| Event | Treatment A: ALXN1840 (Fasted) | Treatment B: ALXN1840 (Fed) | Treatment C: Omeprazole + ALXN1840 (Fasted) |
|---|---|---|---|
| DysphoniaRespiratory, thoracic and mediastinal disorders | 0/18 | 0/18 | 1/18 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 1/18 | 1/18 | 0/18 |
| Nasal drynessRespiratory, thoracic and mediastinal disorders | 1/18 | 0/18 | 0/18 |
| RhinorrhoeaRespiratory, thoracic and mediastinal disorders | 0/18 | 0/18 | 1/18 |
| Abdominal distensionGastrointestinal disorders | 0/18 | 0/18 | 1/18 |
| DiarrhoeaGastrointestinal disorders | 1/18 | 1/18 | 0/18 |
| NauseaGastrointestinal disorders | 0/18 | 1/18 | 0/18 |
| ContusionInjury, poisoning and procedural complications | 1/18 | 0/18 | 0/18 |
| LacerationInjury, poisoning and procedural complications | 0/18 | 0/18 | 1/18 |
| HeadacheNervous system disorders | 1/18 | 0/18 | 1/18 |
All enrolled participants.
| Age, Continuous(years) | Treatment Sequence 1: ABC | Treatment Sequence 2: ACB | Treatment Sequence 3: BAC | Treatment Sequence 4: BCA | Treatment Sequence 5: CAB | Treatment Sequence 6: CBA | Total |
|---|---|---|---|---|---|---|---|
| Mean | 42.3 ± 15.95 | 33.7 ± 16.07 | 25.7 ± 3.06 | 38.0 ± 13.00 | 40.7 ± 11.37 | 31.7 ± 10.97 | 35.3 ± 12.04 |
| Sex: Female, Male(Participants) | Treatment Sequence 1: ABC | Treatment Sequence 2: ACB | Treatment Sequence 3: BAC | Treatment Sequence 4: BCA | Treatment Sequence 5: CAB | Treatment Sequence 6: CBA | Total |
|---|---|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 2 | 3 | 1 | 6 |
| Male | 3 | 3 | 3 | 1 | 0 | 2 | 12 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Apr 2014 to primary completion in May 2014, 1 month.
Results were first posted in Aug 2023, 9 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Tetrathiomolybdate · Omeprazole
Alexion Pharmaceuticals, Inc. →